Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrx Fortamet Paragraph IV Certifications

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of Andrx' Fortamet (metformin extended-release) could be delayed by the company's newly filed Paragraph IV certifications against Bristol-Myers Squibb'sGlucophage XR patents

You may also be interested in...

Andrx Fortamet Clears FDA; Dosing Convenience Over Glucophage XR Will Be Focus

Patients will be able to achieve optimal daily metformin dose with half as many tablets as Glucophage XR and generics. Andrx is also touting the smaller size of the pills. Fortamet will launch in May.

Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization

Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts